aTyr Pharma (ATYR) Competitors $5.56 +0.09 (+1.59%) As of 11:35 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ATYR vs. CGON, BLTE, MESO, ADPT, SRPT, ANIP, ARQT, VCEL, DYN, and APGEShould you be buying aTyr Pharma stock or one of its competitors? The main competitors of aTyr Pharma include CG Oncology (CGON), Belite Bio (BLTE), Mesoblast (MESO), Adaptive Biotechnologies (ADPT), Sarepta Therapeutics (SRPT), ANI Pharmaceuticals (ANIP), Arcutis Biotherapeutics (ARQT), Vericel (VCEL), Dyne Therapeutics (DYN), and Apogee Therapeutics (APGE). These companies are all part of the "pharmaceutical products" industry. aTyr Pharma vs. Its Competitors CG Oncology Belite Bio Mesoblast Adaptive Biotechnologies Sarepta Therapeutics ANI Pharmaceuticals Arcutis Biotherapeutics Vericel Dyne Therapeutics Apogee Therapeutics CG Oncology (NASDAQ:CGON) and aTyr Pharma (NASDAQ:ATYR) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, risk, analyst recommendations, media sentiment, profitability, institutional ownership, earnings and valuation. Is CGON or ATYR more profitable? aTyr Pharma has a net margin of 0.00% compared to CG Oncology's net margin of -15,945.17%. CG Oncology's return on equity of -19.37% beat aTyr Pharma's return on equity.Company Net Margins Return on Equity Return on Assets CG Oncology-15,945.17% -19.37% -18.72% aTyr Pharma N/A -93.69%-68.83% Does the media prefer CGON or ATYR? In the previous week, CG Oncology had 6 more articles in the media than aTyr Pharma. MarketBeat recorded 14 mentions for CG Oncology and 8 mentions for aTyr Pharma. CG Oncology's average media sentiment score of 1.03 beat aTyr Pharma's score of 0.69 indicating that CG Oncology is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CG Oncology 9 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive aTyr Pharma 3 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more volatility and risk, CGON or ATYR? CG Oncology has a beta of 0.87, meaning that its stock price is 13% less volatile than the S&P 500. Comparatively, aTyr Pharma has a beta of 1.01, meaning that its stock price is 1% more volatile than the S&P 500. Which has preferable earnings & valuation, CGON or ATYR? aTyr Pharma has lower revenue, but higher earnings than CG Oncology. CG Oncology is trading at a lower price-to-earnings ratio than aTyr Pharma, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCG Oncology$1.14M2,207.91-$88.04M-$1.77-18.65aTyr Pharma$230K2,341.11-$64.02M-$0.80-6.87 Do insiders and institutionals believe in CGON or ATYR? 26.6% of CG Oncology shares are owned by institutional investors. Comparatively, 61.7% of aTyr Pharma shares are owned by institutional investors. 7.4% of CG Oncology shares are owned by insiders. Comparatively, 3.7% of aTyr Pharma shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Do analysts rate CGON or ATYR? CG Oncology currently has a consensus price target of $54.30, indicating a potential upside of 64.50%. aTyr Pharma has a consensus price target of $23.25, indicating a potential upside of 323.11%. Given aTyr Pharma's stronger consensus rating and higher probable upside, analysts plainly believe aTyr Pharma is more favorable than CG Oncology.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score CG Oncology 0 Sell rating(s) 2 Hold rating(s) 9 Buy rating(s) 1 Strong Buy rating(s) 2.92aTyr Pharma 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 3.17 SummaryaTyr Pharma beats CG Oncology on 9 of the 16 factors compared between the two stocks. Get aTyr Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for ATYR and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ATYR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ATYR vs. The Competition Export to ExcelMetricaTyr PharmaMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$534.54M$3.15B$5.77B$9.87BDividend YieldN/A2.28%6.67%4.51%P/E Ratio-6.8221.0975.6126.46Price / Sales2,341.11471.78551.64120.26Price / CashN/A45.1137.1158.92Price / Book6.629.7711.536.02Net Income-$64.02M-$53.47M$3.29B$266.38M7 Day Performance2.14%0.91%-0.12%-0.53%1 Month Performance5.27%6.59%6.12%3.30%1 Year Performance214.00%11.62%60.95%22.81% aTyr Pharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ATYRaTyr Pharma2.1876 of 5 stars$5.50+0.5%$23.25+323.1%+209.0%$534.54M$230K-6.8253News CoverageOptions VolumeGap UpCGONCG Oncology2.9981 of 5 stars$25.42-5.6%$55.27+117.4%-15.2%$2.05B$1.14M-14.3661News CoveragePositive NewsInsider TradeBLTEBelite Bio2.2907 of 5 stars$63.62-1.2%$96.67+51.9%+34.6%$2.05BN/A-41.0510MESOMesoblast2.2094 of 5 stars$15.71-0.6%$18.00+14.6%+106.4%$2.02B$5.90M0.0080News CoverageGap UpADPTAdaptive Biotechnologies3.3353 of 5 stars$12.67-2.5%$12.38-2.3%+199.3%$1.98B$178.96M-15.45790Positive NewsSRPTSarepta Therapeutics4.8381 of 5 stars$18.06-10.7%$43.50+140.9%-86.3%$1.98B$1.90B-20.761,372Positive NewsANIPANI Pharmaceuticals3.6929 of 5 stars$90.32-0.8%$84.75-6.2%+52.5%$1.97B$614.38M-117.30600Positive NewsInsider TradeARQTArcutis Biotherapeutics1.1647 of 5 stars$15.69-1.8%$19.80+26.2%+55.0%$1.92B$196.54M-20.92150Insider TradeVCELVericel2.3378 of 5 stars$35.79-3.3%$60.33+68.6%-29.8%$1.87B$237.22M298.27300Positive NewsDYNDyne Therapeutics3.6915 of 5 stars$13.00+3.3%$34.07+162.1%-60.8%$1.79BN/A-3.37100News CoveragePositive NewsAPGEApogee Therapeutics3.1893 of 5 stars$36.94-3.5%$99.00+168.0%-20.9%$1.76BN/A-8.9491News CoveragePositive News Related Companies and Tools Related Companies CG Oncology Alternatives Belite Bio Alternatives Mesoblast Alternatives Adaptive Biotechnologies Alternatives Sarepta Therapeutics Alternatives ANI Pharmaceuticals Alternatives Arcutis Biotherapeutics Alternatives Vericel Alternatives Dyne Therapeutics Alternatives Apogee Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ATYR) was last updated on 9/5/2025 by MarketBeat.com Staff From Our PartnersHow “Trump’s New Dollar” Could Impact Your WealthPresident Trump just signed a game-changing law… That could soon upgrade the U.S. dollar in your checking a...Brownstone Research | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | SponsoredWarren Buffett Issues Cryptic Warning on U.S. DollarImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | Sponsored2013 Bitcoin miner reveals his trading system (free)While everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematica...Crypto Swap Profits | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredOne tiny company just cracked Google’s $19B problemAn MIT lab recently cracked a code scientists had been chasing for decades… Turning a “miracle metal” from ...True Market Insiders | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding aTyr Pharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share aTyr Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ATYR Stock Alerts